A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

被引：0
|
作者：
Young, Patricia A.
Mataveli, Fabio D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
  • [42] A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
    Chung, Ki Y.
    Hamadani, Mehdi
    Kahl, Brad S.
    Heffner, Leonard T.
    Caimi, Paolo Fabrizio
    Feingold, Jay Marshall
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Younes, Anas
    Connors, Joseph M.
    Park, Steven I.
    Fanale, Michelle
    O'Meara, Megan M.
    Hunder, Naomi N.
    Huebner, Dirk
    Ansell, Stephen M.
    LANCET ONCOLOGY, 2013, 14 (13): : 1348 - 1356
  • [44] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 53 - 53
  • [45] Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study
    Hong, Ruoxi
    Xia, Wen
    Wang, Liye
    Lee, Kaping
    Lu, Qianyi
    Jiang, Kuikui
    Li, Shengfeng
    Yu, Jinquan
    Wei, Jin
    Tang, Weijia
    Zhou, Danyang
    An, Xin
    Huang, Jiajia
    Xue, Cong
    Bi, Xiwen
    Shi, Yanxia
    Yuan, Zhongyu
    Xu, Fei
    Wang, Shusen
    CANCER COMMUNICATIONS, 2021, 41 (02) : 171 - 182
  • [46] Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    Amorim, Sandy
    Stathis, Anastasios
    Gleeson, Mary
    Iyengar, Sunil
    Magarotto, Valeria
    Leleu, Xavier
    Morschhauser, Franck
    Karlin, Lionel
    Broussais, Florence
    Rezai, Keyvan
    Herait, Patrice
    Kahatt, Carmen
    Lokiec, Francois
    Salles, Gilles
    Facon, Thierry
    Palumbo, Antonio
    Cunningham, David
    Zucca, Emanuele
    Thieblemont, Catherine
    LANCET HAEMATOLOGY, 2016, 3 (04): : E196 - E204
  • [47] Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study
    Bach, Thanh
    Galbiati, Shirley
    Kennedy, Jessie K.
    Deye, Gregory
    Nomicos, Effie Y. H.
    Codd, Ellen E.
    Garcia, Hector H.
    Horton, John
    Gilman, Robert H.
    Gonzalez, Armando E.
    Winokur, Patricia
    An, Guohua
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [48] A Phase 1/2 Open-label, Multiple-dose, Dose-escalation Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients with Angelman Syndrome
    Sell, E.
    Servais, L.
    Harijan, P.
    Stromatt, S.
    Brandabur, M.
    Berry-Kravis, E.
    ANNALS OF NEUROLOGY, 2022, 92 : S163 - S163
  • [49] Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma
    Tolcher, Anthony W.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    Agnew, James
    Lokiec, Francois M.
    Rezai, Keyvan
    Kalambakas, Stacey
    Buchbinder, Aby
    CANCER RESEARCH, 2011, 71
  • [50] A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Burnett, Christine
    Gordon, Gary
    Strack, Thomas
    Lehner, Tara
    Higgins, Jack P.
    Tache, Jason
    BLOOD, 2019, 134
12345